Product Description
Mechanisms of Action: nAChR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: FORUM
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Schizophrenia|Cognitive Dysfunction|Alzheimer Disease
Phase 2: Schizophrenia|Smoking Cessation|Tobacco Use Disorder|Alzheimer Disease
Phase 1: Other|Kidney Diseases|Healthy Volunteers|Affective Disorders, Psychotic|Alzheimer Disease|Psychotic Disorders|Schizophrenia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
EVP-6124-026 | P3 |
Terminated |
Alzheimer Disease |
2017-08-01 |
|
EVP-6124-024 | P3 |
Terminated |
Alzheimer Disease |
2017-01-01 |
|
EVP-6124-025 | P3 |
Terminated |
Alzheimer Disease |
2017-01-01 |
|
EVP-6124-027 | P2 |
Withdrawn |
Alzheimer Disease |
2016-10-01 |